La Jolla-based biopharmaceuticals developer Avidity Biosciences has shuffled its board, saying today that it has named Eric Mosbrooker to its board, with Roderick Wong, M.D. departing. Mosbrooker is the chief operations officer for Cognoa. He also has served as chief commercial officer at Audentes Therapeutics overseeing the gene therapy business unit, in addition to serving at Horizon Pharmaceuticals. Wong is managing partner and chief investment officer at RTW Investments, LP, and had joined the company's board back in November 2019 in conjunction with the company's series C financing.